ABT vs CME · P/E 25, rev $44.33B vs P/E 22, rev $3.59B
Abbott Laboratories (ABT) versus CME Group Inc (CME) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
CME Group Inc (CME) is a financial data & stock exchanges company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported CME revenue for 2026-06-30 was $3.59B. Net income was $2.20B. Revenue was up 90.8% from 2026-03-31 to 2026-06-30. CME currently screens at market cap $91.25B and trailing P/E 21.9.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. CME currently screens at market cap $91.25B and trailing P/E 21.9.
Not investment advice. Open the ABT and CME stock pages for the full models.
Not investment advice.